Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urology and Nephrology 2021 December;73(6) > Minerva Urology and Nephrology 2021 December;73(6):870-2

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

EDITORIAL COMMENT   

Minerva Urology and Nephrology 2021 December;73(6):870-2

DOI: 10.23736/S2724-6051.21.04817-5

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?

Fabio TURCO 1, Marcello TUCCI 2, Consuelo BUTTIGLIERO 1

1 Division of Medical Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy; 2 Department of Medical Oncology, Cardinal Massaia Hospital, Asti, Italy



top of page